898 related articles for article (PubMed ID: 33168643)
1. The Pharmacological Case for Cannabigerol.
Nachnani R; Raup-Konsavage WM; Vrana KE
J Pharmacol Exp Ther; 2021 Feb; 376(2):204-212. PubMed ID: 33168643
[TBL] [Abstract][Full Text] [Related]
2. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
3. The Origin and Biomedical Relevance of Cannabigerol.
Jastrząb A; Jarocka-Karpowicz I; Skrzydlewska E
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887277
[TBL] [Abstract][Full Text] [Related]
4. CBG, CBD, Δ9-THC, CBN, CBGA, CBDA and Δ9-THCA as antioxidant agents and their intervention abilities in antioxidant action.
Dawidowicz AL; Olszowy-Tomczyk M; Typek R
Fitoterapia; 2021 Jul; 152():104915. PubMed ID: 33964342
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
6. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.
Perez E; Fernandez JR; Fitzgerald C; Rouzard K; Tamura M; Savile C
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056807
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.
Calapai F; Cardia L; Esposito E; Ammendolia I; Mondello C; Lo Giudice R; Gangemi S; Calapai G; Mannucci C
Evid Based Complement Alternat Med; 2022; 2022():3336516. PubMed ID: 36397993
[TBL] [Abstract][Full Text] [Related]
9. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Salami SA; Martinelli F; Giovino A; Bachari A; Arad N; Mantri N
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899626
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of
Henshaw FR; Dewsbury LS; Lim CK; Steiner GZ
Cannabis Cannabinoid Res; 2021 Jun; 6(3):177-195. PubMed ID: 33998900
[No Abstract] [Full Text] [Related]
11. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
De Petrocellis L; Vellani V; Schiano-Moriello A; Marini P; Magherini PC; Orlando P; Di Marzo V
J Pharmacol Exp Ther; 2008 Jun; 325(3):1007-15. PubMed ID: 18354058
[TBL] [Abstract][Full Text] [Related]
12. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
Blebea NM; Pricopie AI; Vlad RA; Hancu G
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673788
[TBL] [Abstract][Full Text] [Related]
13. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol.
Pagano E; Montanaro V; Di Girolamo A; Pistone A; Altieri V; Zjawiony JK; Izzo AA; Capasso R
Nat Prod Commun; 2015 Jun; 10(6):1009-12. PubMed ID: 26197538
[TBL] [Abstract][Full Text] [Related]
14. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
15.
Sepulveda DE; Vrana KE; Kellogg JJ; Bisanz JE; Desai D; Graziane NM; Raup-Konsavage WM
J Pharmacol Exp Ther; 2024 May; ():. PubMed ID: 38777605
[TBL] [Abstract][Full Text] [Related]
16. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.
Rock EM; Goodwin JM; Limebeer CL; Breuer A; Pertwee RG; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2011 Jun; 215(3):505-12. PubMed ID: 21243485
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids in clinical practice.
Williamson EM; Evans FJ
Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pharmacology of Phytocannabinoids.
Turner SE; Williams CM; Iversen L; Whalley BJ
Prog Chem Org Nat Prod; 2017; 103():61-101. PubMed ID: 28120231
[TBL] [Abstract][Full Text] [Related]
19. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
20. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.
Brierley DI; Samuels J; Duncan M; Whalley BJ; Williams CM
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3603-13. PubMed ID: 27503475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
